by David Eyre | Mar 4, 2026 | US & International
Background REGENXBIO and the Trustees of the University of Pennsylvania sued Sarepta for infringing multiple claims of U.S. Patent No. 10,526,617, which is directed to cultured host cells containing a recombinant nucleic acid molecule encoding an AAV capsid sequence...
by David Eyre | Feb 18, 2026 | US & International
This case is important because it allows the Supreme Court to define the point of balance between enforcement of patent rights for medical uses and the competition in the market place for generic pharmaceuticals. Consequently, the ruling of the Supreme Court will have...
by Ben Snipe | Feb 13, 2026 | UK
Alison joined Schlich as a Legal Secretary in November 2025 having established her administrative / organisational skills over 19 years in the Medical Communication industry. During her time working in the Medical Communication industry, Alison worked her way up from...
by Sean Hutchinson | Feb 10, 2026 | EPO
Background The Enlarged Board of Appeal’s decision in G 1/23 caused a significant change in practice at the European Patent Office (“EPO”), resulting in a product made publicly available before the priority date which the skilled person could not have reproduced now...
by Sean Hutchinson | Feb 5, 2026 | US & International
In many countries, patents are granted for inventions and last for 20 years, subject to payment of renewal fees at regular intervals. However, some countries permit the patent term to be extended provided certain requirements are met. In the UK and the EU, a...
by Sean Hughes | Jan 28, 2026 | US & International
At its core, the decision reinforces a stringent US approach to patent sufficiency: if a patent specification does not clearly support and enable the full scope of the claims at the priority date, those claims are vulnerable, no matter how valuable the underlying...
Recent Comments